RxDoctor Payments Data

Sarfraz Ahmad, MD

Gastroenterology · Mt Pleasant, PANPI 1073501052

Payments from drug & device makers

$982in general payments, 2019–2025

Across 49 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$491
  • Johnson & Johnson$168
  • Boston Scientific$116
  • Pfizer$75
  • Regeneron Healthcare Solutions, Inc.$33
  • Novo Nordisk$31
  • plus $68 from 5 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982 in reported general payments places this provider in the 35th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$89,066
Medicare patients
392
Services billed
720

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase41$101,754
Mesalamine75$30,238
LinzessLinaclotide36$24,640
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates290$19,416
Colestipol Hcl56$10,263
Pantoprazole Sodium787$7,519
TrulancePlecanatide13$7,020
AmitizaLubiprostone12$4,621
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg155$3,305
ClenpiqSod Picosulf/Mag Ox/Citric Ac19$3,156
Mesalamine ErMesalamine12$2,824
Sucralfate39$2,648
Omeprazole161$2,152
SutabSod Sulf/Pot Chloride/Mag Sulf12$1,879
Lubiprostone17$1,748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$491$126,39477 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Mt Pleasant

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →